Basics of immune responses in transplantation in preparation for application of composite tissue allografts in plastic and reconstructive surgery: Part I

Plastic and Reconstructive Surgery

Volumn 121, Issue 1, 2008, Pages

  Siemionow, Maria ^a   Klimczak, Aleksandra ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CYCLOSPORIN; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGRAFT; CELL FUNCTION; CLINICAL PRACTICE; COMPOSITE GRAFT; DIABETES MELLITUS; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; GRAFT SURVIVAL; HELPER CELL; HISTOCOMPATIBILITY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE RESPONSE; LEUKOPENIA; NATURAL KILLER CELL; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PLASTIC SURGERY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TRANSPLANTATION; XENOGRAFT;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; TISSUE TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 38049094287     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.prs.0000299470.95855.ce     Document Type: Review

References (54)

1. Dubernard, J. M., Owen, E., Herzberg, G., et al. Human hand allograft: Report on first 6 months. Lancet 353: 1315, 1999.
2. Strome, M., Stein, J., and Esclamado, R. Laryngeal transplantation and 40-month follow-up. N. Engl. J. Med. 344: 1676, 2001.
3. Petit, F., Minns, A. B., Dubernard, J., et al. Composite tissue allotransplantation and reconstructive surgery: First clinical applications. Ann. Surg. 237: 19, 2003.
4. Hettiaratchy, S., Randolph, M. A., Petit, F., et al. Composite tissue allotransplantation: A new era in plastic surgery? Br. J. Plast. Surg. 57: 381, 2004.
5. Levi, D. M., Tzakis, A. G., Kato, T., et al. Transplantation of the abdominal wall. Lancet 361: 2173, 2003.
6. Devauchelle, B., Badet, L., Lengele, B., et al. First human face allograft: Early report. Lancet 368: 203, 2006.
7. Lee, A. W. P., Yaremchuk, M. J., Pan, Y. C., et al. Relative antigenicity of components of a vascularized limb allograft. Plast. Reconstr. Surg. 87: 401, 1991.
8. Buttemeyer, R., Jones, N. F., Min, Z., et al. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine. Plast. Reconstr. Surg. 97: 139, 1996.
9. Roitt, I., Brostoff, J., and Male, D. Immunology, 5th Ed. London: Mosby International, 1998.
10. Aw, M. M. Transplant immunology. J. Pediatr. Surg. 38: 1275, 2003.
11. Sayegh, M. H., and Turka, L. A. The role of T-cell costimulatory activation pathways in transplant rejection. N. Engl. J. Med. 338: 1813, 1998.
12. Gimmi, C. D., Freeman, G. J., Gribben, J., et al. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. U.S.A. 90: 6586, 1993.
13. Noel, P. J., Boise, L. H., Green, J., et al. CD28 costimulation prevents cell death during primary T cell activation. J. Immunol. 157: 636, 1996.
14. Rogers, N. J., and Lechler, R. I. Allorecognition. Am. J. Transplant. 1: 97, 2001.
15. Womer, K. L., Sayegh, M. H., and Auchincloss, H., Jr. Involvement of the direct and indirect pathways of allorecognition in tolerance induction. Phil. Trans. R. Soc. Lond. B Biol. Sci. 356: 639, 2001.
16. Ensminger, S. M., Spriewald, B. M., Witzke, O., et al. Indirect allorecognition can play an important role in the development of transplant arteriosclerosis. Transplantation 73: 279, 2002.
17. Raulet, D. H., and Vance, R. E. Self-tolerance of natural killer cells. Nat. Rev. Immunol. 6: 520, 2006.
18. Kean, L. S., Hamby, K., Koehn, B., et al. NK cells mediate costimulation blockade-resistant rejection of allogeneic stem cells during nonmyeloablative transplantation. Am. J. Transplant. 6: 292, 2006.
19. Kitchens, W. H., Uehara, S., Chase, C. M., et al. The changing role of natural killer cells in solid organ rejection and tolerance. Transplantation 81: 811, 2006.
20. McNerney, M. E., Lee, K. M., Zhou, P., et al. Role of natural killer cell subsets in cardiac allograft rejection. Am. J. Transplant. 6: 505, 2006.
21. Yu, G., Xu, X., Vu, M. D., et al. NK cells promote transplant tolerance by killing donor antigen-presenting cells. J. Exp. Med. 203: 1851, 2006.
22. Cendales, L. C., Kirk, A. D., Moresi, J. M., et al. Composite tissue allotransplantation: Classification of clinical acute skin rejection. Transplantation 80: 1676, 2005.
23. Nakashima, S., Qian, Z., Rahimi, S., et al. Membrane attack complex contributes to destruction of vascular integrity in acute lung allograft rejection. J. Immunol. 169: 4620, 2002.
24. Rocha, P. N., Plumb, T. J., Crowley, S., et al. Effector mechanisms in transplant rejection. Immunol. Rev. 196: 51, 2003.
25. Hancock, W. W., Gao, W., Shemmeri, N., et al. Immunopathogenesis of accelerated allograft rejection in sensitized recipients: Humoral and nonhumoral mechanisms. Transplantation 73: 1392, 2002.
26. Kanitakis, J., Jullien, D., Petruzzo, P., et al. Clinicopathologic features of graft rejection of the first human hand allograft. Transplantation 76: 688, 2003.
27. Kanitakis, J., Badet, L., Petruzzo, P., et al. First human face allotransplantation: Monitoring of rejection with a pathological score assessing human composite tissue allograft rejection (Abstract 967). Transplantation 82(Suppl. 3): 392, 2006.
28. Williams, J. M., Holzknecht, Z. E., Plummer, T., et al. Acute vascular rejection and accommodation: Divergent outcomes of the humoral response to organ transplantation. Transplantation 78: 1471, 2004.
29. Moll, S., and Pascual, M. Humoral rejection of organ allografts. Am. J. Transplant. 5: 2611, 2005.
30. Racusen, L. C., Halloran, P. F., and Solez, K. Banff 2003 meeting report: New diagnostic insights and standards. Am. J. Transplant. 4: 1562, 2004.
31. Petruzzo, P., Badet, L., Gazarian, A., et al. Bilateral hand transplantation: Six years after the first case. Am. J. Transplant. 6: 1718, 2006.
32. Cendales, L. C., Xu, H., Bacher, J., et al. Composite tissue allotransplantation: Development of a preclinical model in nonhuman primates. Transplantation 80: 1447, 2005.
33. Womer, K. L., Vella, J. P., and Sayegh, M. H. Chronic allograft dysfunction: Mechanisms and new approaches to therapy. Semin. Nephrol. 20: 126, 2000.
34. Womer, K. L., Lee, R. S., Madsen, J., et al. Tolerance and chronic rejection. Phil. Trans. R. Soc. Lond. B Biol. Sci. 356: 727, 2001.
35. Joosten, S. A., Sijpkens, Y. W., van Kooten, C., et al. Chronic renal allograft rejection: Pathophysiologic considerations. Kidney. Int. 68: 1, 2005.
36. Tullius, S. G., and Tilney, N. L. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 59: 313, 1995.
37. Lee, R. S., Yamada, K., Houser, S., et al. Indirect allorecognition promotes the development of cardiac allograft vasculopathy. Transplant. Proc. 33: 308, 2001.
38. Womer, K. L., Stone, J. R., Murphy, B., et al. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J. Am. Soc. Nephrol. 12: 2500, 2001.
39. Takada, M., Nadeau, K. C., Hancock, W., et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 65: 1533, 1998.
40. Singer, P., Shapiro, H., and Cohen, J. Brain death and organ damage: The modulating effects of nutrition. Transplantation 80: 1363, 2005.
41. Kuecuek, O., Mantouvalou, L., Klemz, R., et al. Significant reduction of proinflammatory cytokines by treatment of the brain-dead donor. Transplant. Proc. 37: 387, 2005.
42. Coulson, M. T., Jablonski, P., Howden, B. O., et al. Beyond operational tolerance: Effect of ischemic injury on development of chronic damage in renal grafts. Transplantation 80: 353, 2005.
43. Takada, M., Nadeau, K. C., Shaw, G., et al. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney: Inhibition by a soluble P-selectin ligand. J. Clin. Invest. 99: 2682, 1997.
44. Gorantla, V. S., Barker, J. H., Jones, J. W., Jr., et al. Immunosuppressive agents in transplantation: Mechanism of action and current anti-rejection strategies. Microsurgery 20: 420, 2000.
45. Yu, X., Carpenter, P., and Anasetti, C. Advances in transplantation tolerance. Lancet 357: 1959, 2001.
46. Fehr, T., and Sykes, M. Tolerance induction in clinical transplantation. Transpl. Immunol. 13: 117, 2004.
47. Starzl, T. E., Murase, N., Abu-Elmagd, K., et al. Tolerogenic immunosuppression for organ transplantation. Lancet 361: 1502, 2003.
48. Gerber, D. A., Bonham, C. A., and Thomson, A. W. Immunosuppressive agents: Recent developments in molecular action and clinical application. Transplant Proc. 30: 1573, 1998.
49. Allison, A. C., and Eugui, E. M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47: 85, 2000.
50. Saunders, R. N., Metcalfe, M. S., and Nicholson, L. Rapamycin in transplantation: A review of the evidence. Kidney. Int. 59: 3, 2001.
51. Petruzzo, P., Revillard, J. P., Kanitakis, J., et al. First human double hand transplantation: Efficacy of a conventional immunosuppressive protocol. Clin. Transplant. 17: 455, 2003.
52. Buell, J. F., Gross, T. G., and Woodle, E. S. Malignancy after transplantation. Transplantation 80(2 Suppl.): S254, 2005.
53. Engl, T., Makarevic, J., Relja, B., et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: Impact on tumor recurrence and malignancy. B.M.C. Cancer 5: 4, 2005.
54. Cherikh, W. S., Kauffman, H. M., McBride, M. A., et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 76: 1289, 2003.